Breast Care · 2011 · 49 citations · 71 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyTumor HeterogeneityBreast Cancer OncologyBreast Cancer RecurrenceCancer ProgressionMalignant NeoplasmsMetastatic Breast CancerBrca1 InactivationBreast Cancer HistologyBreast Cancer HistopathologyBreast Cancer Molecular SubtypesHer2 AmplificationHer2 ExpressionTriple-negative Breast Cancer RecurrenceTumor Cell Proliferation
SUMMARY: Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptors and the lack of HER2 expression or amplification. Much interest has recently been focused on these triple-negative (TN) subtypes because they may be aggressive and are more likely to recur and metastasize than other subtypes of breast cancer. TNBC accounts for approximately 10-24% of all breast cancer cases, and typically it occurs in younger patients and in patients with BRCA1 mutation. There is a substantial heterogeneity of TNBCs both at the morphological and the molecular level, but there are also common features, such as low tumor grade and accelerated tumor proliferation. Morphologically, TNBC may present as invasive ductal, metaplastic, medullary, apocrine, or other types. Molecularly, they are most frequently associated with a basal phenotype, but there is a distinct subgroup of cancers that are not of basal type and belong to the claudin-low or molecular-apocrine type. The basal phenotype is frequently associated with the loss of BRCA1.
71
Molecular portraits of human breast tumours
Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 2009 · 4.9K citations · Full text
Medicine, Bioinformatics, Oncology +16